Cellectis S.A.

Healthcare · Biotechnology · France

Last price 1.08 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 84.26M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with...